Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome

Journal of Cutaneous Pathology

Volumn 39, Issue 5, 2012, Pages 500-507

  Goswami, Meghali ^a   Duvic, Madeleine ^a   Dougherty, Alexis ^a   Ni, Xia ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Unit 1452   (United States)

Author keywords

c myc; mycosis fungoides; p53; S zary syndrome; Twist

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; MYCOSIS FUNGOIDES; PATHOLOGY; SEZARY SYNDROME; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; SEZARY SYNDROME; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TWIST TRANSCRIPTION FACTOR;

EID: 84860206516     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2012.01883.x     Document Type: Article

References (43)

1. Jones D, Dang NH, Duvic M, Washington LT, Huh YO., Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115: 885.
2. Rappl G, Abken H, Muche JM, et al., CD4+CD7- leukemic T cells from patients with Sezary syndrome are protected from galectin-1-triggered T cell death. Leukemia 2002; 16: 840.
3. Washington LT, Huh YO, Powers LC, Duvic M, Jones D., A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2002; 2: 5.
4. Agar NS, Wedgeworth E, Crichton S, et al., Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730.
5. Vidulich KA, Talpur R, Bassett RL, Duvic M., Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009; 48: 243.
6. Ni X, Zhang C, Talpur R, Duvic M., Resistance to activation-induced cell death and bystander cytotoxicity via the Fas//Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Investig Dermatol 2005; 124: 741.
7. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS., Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol 2009; 129: 1165.
8. Jones CL, Wain EM, Chu CC, et al., Downregulation of fas gene expression in sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 2010; 130: 1116.
9. Duvic M, Foss FM., Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol 2007; 34 (6 Suppl. 5): S21.
10. Thisse B, el Messal M, Perrin-Schmitt F. The twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res 1987; 15: 3439.
11. Spicer DB, Rhee J, Cheung WL, Lassar AB., Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist. Science 1996; 272: 1476.
12. Wang SM, Coljee VW, Pignolo RJ, Rotenberg MO, Cristofalo VJ, Sierra F., Cloning of the human twist gene: its expression is retained in adult mesodermally-derived tissues. Gene 1997; 187: 83.
13. Chen ZF, Behringer RR., Twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 1995; 9: 686.
14. Maestro R, Dei Tos AP, Hamamori Y, et al., Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999; 13: 2207.
15. Puisieux A, Valsesia-Wittmann S, Ansieau S., A twist for survival and cancer progression. Br J Cancer 2006; 94: 13.
16. Rosivatz E, Becker I, Specht K, et al., Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881.
17. Watanabe O, Imamura H, Shimizu T, et al., Expression of twist and wnt in human breast cancer. Anticancer Res 2004; 24: 3851.
18. Kwok WK, Ling MT, Lee TW, et al., Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65: 5153.
19. Cheng GZ, Zhang WZ, Sun M, et al., Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008; 283: 14665.
20. Lo HW, Hsu SC, Xia W, et al., Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007; 67: 9066.
21. Ling X, Arlinghaus RB., Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005; 65: 2532.
22. Cosset E, Hamdan G, Jeanpierre S, et al., Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 2011; 117: 1673.
23. Baer R., TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol 1993; 4: 341.
24. van Doorn R, Dijkman R, Vermeer MH, et al., Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578.
25. Ni X, Richmond HM, Liao XM, et al., Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 2008; 128: 2631.
26. Vermeer MH, van Doorn R, Dijkman R, et al., Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res 2008; 68: 2689.
27. van Doorn R, van Kester MS, Dijkman R, et al., Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113: 127.
28. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M., Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001; 7: 2682.
29. Olsen E, Vonderheid E, Pimpinelli N, et al., Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713.
30. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R., Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150.
31. Oren M, Maltzman W, Levine AJ., Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1981; 1: 101.
32. Kanavaros P, Ioannidou D, Tzardi M, et al., Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. Pathol Res Pract 1994; 190: 767.
33. Saglio G, Emanuel BS, Guerrasio A, et al., 3' c-myc rearrangement in a human leukemic T-cell line. Cancer Res 1986; 46: 1413.
34. Li G, Chooback L, Wolfe JT, et al., Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol 1998; 110: 767.
35. McGregor JM, Crook T, Fraser-Andrews EA, et al., Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol 1999; 112: 317.
36. Campbell JJ, Clark RA, Watanabe R, Kupper TS., Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116: 767.
37. Niesner U, Albrecht I, Janke M, et al., Autoregulation of Th1-mediated inflammation by twist1. J Exp Med 2008; 205: 1889.
38. Sommer VH, Clemmensen OJ, Nielsen O, et al., In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004; 18: 1288.
39. Brender C, Nielsen M, Kaltoft K, et al., STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001; 97: 1056.
40. Duvic M, Talpur R, Ni X, et al., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31.
41. Verma NK, Davies AM, Long A, Kelleher D, Volkov Y., STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett 2010; 15: 342.
42. Whittaker S., Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol 2006; 33 (1 Suppl. 3): S3.
43. Koh HS, Lee C, Lee KS, et al., Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells. Mol Cells 2009; 28: 553.